Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals has issued 264,943 fully paid ordinary shares to satisfy a US$4 million deferred payment related to its acquisition of U.S.-based ImaginAb, Inc., a deal previously disclosed to the market. The company stated that the shares were issued without a disclosure document under the Corporations Act and confirmed it is up to date with its financial reporting and continuous disclosure obligations, with no undisclosed material information, reinforcing transparency around the share issue and the acquisition’s completion.
This latest share issuance finalises a deferred consideration component of the ImaginAb acquisition, underlining Telix’s commitment to integrating the acquired business into its operations. By settling the obligation in shares, Telix preserves cash while reinforcing investor awareness of its compliance posture, which may support confidence among shareholders and other stakeholders regarding governance and regulatory adherence.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$22.40 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company listed on the ASX that focuses on developing and commercialising radiopharmaceuticals for the diagnosis and treatment of cancer. The company operates in the oncology space and expands its portfolio through strategic acquisitions to strengthen its position in molecular imaging and targeted therapeutics.
Average Trading Volume: 3,042,513
Technical Sentiment Signal: Buy
Current Market Cap: A$5.16B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.